ESTRACAP Trademark

Trademark Overview


On Wednesday, September 10, 2014, a trademark application was filed for ESTRACAP with the United States Patent and Trademark Office. The USPTO has given the ESTRACAP trademark a serial number of 86391317. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 16, 2018. This trademark is owned by Actavis, Inc.. The ESTRACAP trademark is filed in the Pharmaceutical Products category with the following description:

Contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pha...
estracap

General Information


Serial Number86391317
Word MarkESTRACAP
Filing DateWednesday, September 10, 2014
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 16, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 13, 2015

Trademark Statements


Goods and ServicesContraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceuticals preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antimicrobial for inhibiting microbiological decomposition in pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 18, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameALLERGAN FINANCE, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressPARSIPPANY, NJ 07054

Party NameActavis, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameActavis, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, April 16, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, April 16, 2018ABANDONMENT - NO USE STATEMENT FILED
Wednesday, January 3, 2018ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, September 20, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 19, 2017EXTENSION 5 GRANTED
Thursday, September 7, 2017EXTENSION 5 FILED
Thursday, September 7, 2017TEAS EXTENSION RECEIVED
Friday, March 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 16, 2017EXTENSION 4 GRANTED
Wednesday, March 1, 2017EXTENSION 4 FILED
Wednesday, March 8, 2017AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, March 1, 2017TEAS EXTENSION RECEIVED
Monday, January 30, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 9, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 8, 2016EXTENSION 3 GRANTED
Tuesday, August 30, 2016EXTENSION 3 FILED
Tuesday, August 30, 2016TEAS EXTENSION RECEIVED
Saturday, April 9, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 8, 2016EXTENSION 2 GRANTED
Wednesday, March 9, 2016EXTENSION 2 FILED
Wednesday, April 6, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, March 9, 2016TEAS EXTENSION RECEIVED
Wednesday, September 23, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 22, 2015EXTENSION 1 GRANTED
Wednesday, September 9, 2015EXTENSION 1 FILED
Monday, September 21, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 9, 2015TEAS EXTENSION RECEIVED
Tuesday, March 10, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 13, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 13, 2015PUBLISHED FOR OPPOSITION
Wednesday, December 24, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 10, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, December 10, 2014ASSIGNED TO LIE
Wednesday, November 26, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 25, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 24, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 24, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, November 1, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, November 1, 2014NON-FINAL ACTION E-MAILED
Saturday, November 1, 2014NON-FINAL ACTION WRITTEN
Thursday, October 30, 2014ASSIGNED TO EXAMINER
Thursday, September 18, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, September 13, 2014NEW APPLICATION ENTERED IN TRAM